CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02197 CLOVER BIO-B

Not Yet Opened 08-26 16:08:03

2.300

+0.000

0.00%

High2.360	Low2.250	Vol3.53M
Open2.290	D1 Closing2.300	Amplitude4.78%
Mkt Cap2.99B	Tradable Cap2.99B	Total Shares1.30B
T/O8.11M	T/O Rate0.27%	Tradable Shares1.30B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02197","market":"HK","secType":"STK","nameCN":"CLOVER BIO-B","latestPrice":2.3,"timestamp":1787731683003,"preClose":2.3,"halted":0,"volume":3528500,"delay":0,"changeRate":0,"floatShares":1298000000,"shares":1298000000,"eps":-0.1897836525542639,"marketStatus":"Not Yet Opened","change":0,"latestTime":"08-26 16:08:03","open":2.29,"high":2.36,"low":2.25,"amount":8107435,"amplitude":0.047826,"askPrice":2.31,"askSize":3000,"bidPrice":2.3,"bidSize":35500,"shortable":3,"etf":0,"ttmEps":-0.1897836525542639,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787794200000},"marketStatusCode":0,"adr":0,"listingDate":1636041600000,"exchange":"SEHK","adjPreClose":2.3,"openAndCloseTimeList":[[1787707800000,1787716800000],[1787720400000,1787731200000]],"volumeRatio":1.0548264625523809,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02197/wiki","defaultTab":"wiki","newsList":[{"id":"1142078584","title":"Clover posts RMB0.95 billion interim profit for H1 2026, propelled by one-off GAVI settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=1142078584","media":"Bulletin Express","labels":["SGX"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1142078584?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:26","pubTimestamp":1787696765,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals (Clover) reported a sharp earnings turnaround for the six months ended 30 June 2026, booking net profit of RMB0.95 billion versus a RMB0.10 billion loss a year earlier. The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Clover posts RMB0.95 billion interim profit for H1 2026, propelled by one-off GAVI settlement","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715724","title":"Clover Biopharma Returns to Profit in H1 FY26 at RMB 954.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715724","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715724?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:43","pubTimestamp":1787744594,"startTime":"0","endTime":"0","summary":"Clover Biopharma returns to profit in H1 FY26 at RMB 954.98 millionClover Biopharmaceuticals swung to an IFRS profit of RMB 954.98 million, reflecting a one-off GAVI settlement gain.Revenue fell 94.5%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL4d5M8C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139951385","title":"Clover Biopharmaceuticals Flips to Profit in First-Half Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1139951385","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139951385?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:40","pubTimestamp":1787697612,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals-B (02197) reported a net profit attributable to parent shareholders of 955 million yuan for the six months ended June 30, 2026, marking a turnaround from a loss in the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662505547","title":"China's Clover Biopharma H1 Revenue Drops Sharply, Flags Going-Concern Doubt","url":"https://stock-news.laohu8.com/highlight/detail?id=2662505547","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662505547?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:24","pubTimestamp":1787696645,"startTime":"0","endTime":"0","summary":"China's Clover Biopharma H1 revenue drops sharply, flags going-concern doubtOverviewChina vaccine developer's H1 revenue dropped sharply after ending AdimFlu-S (QIS) sales in ChinaCompany swung to net","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M103:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","LU0244354667.USD","01801","LU2488822045.USD","BK1161","LU2097828714.EUR","02197","LU0463099449.HKD","BK1589","BK1583","HK0000165453.HKD","LU2097828805.USD","06118","LU2097828631.EUR","LU1188198961.HKD","LU2097828474.EUR","LU0326950275.SGD","BK1141","KURE","LU0455707207.USD","LU1969619763.USD","LU2097828557.USD","LU2328871848.SGD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775779","title":"Clover Biopharmaceuticals H1 Revenue RMB 179 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662775779?lang=en_us&edition=fundamental","pubTime":"2026-08-26 06:09","pubTimestamp":1787695742,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLX5WMNXC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198595840","title":"Clover Biopharmaceuticals Sets 25 Aug 2026 Board Meeting to Approve 1H26 Results and Mull Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1198595840","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198595840?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:07","pubTimestamp":1786612025,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals has scheduled a board meeting for Tuesday, 25 August 2026 in Shanghai. Directors will review and approve the consolidated interim results for the six months ended 30 June...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659132135","title":"Clover Biopharma Sets Board Meeting to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2659132135","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659132135?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:32","pubTimestamp":1786609940,"startTime":"0","endTime":"0","summary":"Clover Biopharma sets board meeting to review interim results, consider dividendClover Biopharmaceuticals will hold a board meeting on Aug. 25, 2026.Directors will review interim results for the six m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6Mck2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654055822","title":"With Clover Biopharmaceuticals Up 10%, Insider Buyers Count Their Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2654055822","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654055822?lang=en_us&edition=fundamental","pubTime":"2026-07-25 07:34","pubTimestamp":1784936049,"startTime":"0","endTime":"0","summary":"Insiders who bought Clover Biopharmaceuticals, Ltd. ( HKG:2197 ) stock in the last 12 months were richly rewarded last...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2197/clover-biopharmaceuticals-shares/news/with-clover-biopharmaceuticals-up-10-insider-buyers-count-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2197/clover-biopharmaceuticals-shares/news/with-clover-biopharmaceuticals-up-10-insider-buyers-count-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653120917","title":"Cellectar Biosciences Publishes Corporate Presentation on Phospholipid Drug Conjugate Radiotherapy Pipeline, Led by Iopofosine I-131 in Waldenstrom Macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653120917","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653120917?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:41","pubTimestamp":1784648515,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemiaCellectar BioSciences outlined plan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL6R2kRw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","02197","CLRB","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108650143","title":"CLOVER BIO-B Anticipates Mid-Year Profit Turnaround with Projected Net Income of 9.57 to 12.04 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1108650143","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108650143?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:10","pubTimestamp":1784502621,"startTime":"0","endTime":"0","summary":"The biotechnology firm CLOVER BIO-B (02197) has issued a positive profit alert for the first half of the year.For the six-month period ending June 30, 2026, the group expects to record a net profit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652268549","title":"Clover Biopharmaceuticals - Expects Net Profit of Rmb957 Mln–rmb1204 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652268549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652268549?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:04","pubTimestamp":1784502272,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nFWN43J0TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198338149","title":"Clover Biopharma Reports No Share Changes in June; 1.30 Billion Shares Remain Outstanding","url":"https://stock-news.laohu8.com/highlight/detail?id=1198338149","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198338149?lang=en_us&edition=fundamental","pubTime":"2026-07-03 17:24","pubTimestamp":1783070663,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. released its monthly return for the period ended 30 June 2026, confirming that the company’s capital structure was unchanged during the month. The authorised share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159240019","title":"CLOVER BIO-B Adopts Sixth Amended & Restated Memorandum and Articles of Association; Authorised Share Capital Fixed at US$0.20 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1159240019","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159240019?lang=en_us&edition=fundamental","pubTime":"2026-06-18 22:04","pubTimestamp":1781791489,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. (“Clover Bio-B”, HKEX: 02197) has approved its Sixth Amended and Restated Memorandum and Articles of Association (“6th M&A”) by special resolution dated 18 June 2026....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644890830","title":"Clover Biopharma shareholders adopt financial statements, re-elect directors at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2644890830","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644890830?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:57","pubTimestamp":1781791023,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals held its annual general meeting on June 18, 2026.Shareholders adopted the audited consolidated financial statements and the directors’ and auditor’s reports for the year ended Dec. 31, 2025.Shareholders passed a mandate for the board to allot and issue shares or sell or transfer treasury shares, subject to the stated limit.Shareholders passed a mandate for the board to repurchase shares, subject to the stated limit, with a related extension of the issuance mandate.Shareholders adopted amendments to the memorandum and articles of association, approving the sixth amended and restated version to replace the existing one.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7RcC3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162671823","title":"Clover Bio-B Strengthens Internal Controls on Share Trading After Model Code Lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=1162671823","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162671823?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:26","pubTimestamp":1780658798,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. (Clover Bio-B, 02197) released a supplemental announcement on 5 June 2026 detailing additional measures to bolster compliance with the Hong Kong Listing Rules’ Model...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641112062","title":"Clover Biopharma tightens share-trading controls for grantors after Model Code breaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2641112062","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641112062?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:08","pubTimestamp":1780657717,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals issued a supplemental clarification on Model Code compliance disclosures in its FY2025 results announcement and annual report.Management told share grantors to follow the Model Code, circulated updated share-dealing compliance guidelines.Controls to tighten oversight include blackout-period notifications, pre-clearance by Dr. Peng Liang, post-trade reporting, recurring training, quarterly compliance check-ins.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Biopharmaceuticals Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDLc2XgDr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105680932","title":"Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=1105680932","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105680932?lang=en_us&edition=fundamental","pubTime":"2026-06-03 16:45","pubTimestamp":1780476317,"startTime":"0","endTime":"0","summary":"Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises. • Issued...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640964676","title":"Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2640964676","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640964676?lang=en_us&edition=fundamental","pubTime":"2026-06-02 04:12","pubTimestamp":1780344740,"startTime":"0","endTime":"0","summary":"Cellectar BioSciences posts corporate presentation on iopofosine I-131 path toward accelerated approval in Waldenstrom macroglobulinemia. Updated CLOVER-WaM efficacy showed ORR 83.6% and MRR 61.8% in the evaluable population; median duration of response 17.8 months.Median progression-free survival was 13.5 months; earlier-line patients showed longer median duration of response at 21.2 months.Regulatory strategy centered on a U.S. accelerated approval filing using CLOVER-WaM data; potential approval targeted for 2027.Phase 3 confirmatory study planned in post-BTK inhibitor patients, 200 total enrollment; estimated total study cost USD 42 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the ori","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL7P2lPX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","BK1161","02197","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640695184","title":"Cellectar says iopofosine I-131 posts 79.2% major response rate in Phase 2 CLOVER-WaM subgroup after BTK inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640695184","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640695184?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:10","pubTimestamp":1780315825,"startTime":"0","endTime":"0","summary":"Cellectar Biosciences will present new Phase 2b CLOVER WaM subgroup results at ASCO on June 1, 2026.The analysis showed strong, durable responses for iopofosine I 131 in relapsed or refractory Waldenstrm macroglobulinemia following BTK inhibitor therapy.Tolerability was described as manageable, with severe side effects limited to blood-count reductions.The data supported a plan to seek US accelerated approval, with a Phase 3 confirmatory trial targeted for 4Q26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL2jpB4g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLRB","02197","BK1161","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139664896","title":"Clover Biopharm sets 18 June 2026 AGM; targets 10% buy-back, 20% new-issue headroom and constitutional overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=1139664896","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139664896?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:04","pubTimestamp":1779786242,"startTime":"0","endTime":"0","summary":"Key points   • AGM timetable: Clover Biopharmaceuticals will hold its 2026 annual general meeting on 18 June 2026 at 10:00 a.m. in Chengdu. The register of members closes 15–18 June; shareholders...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cloverbiopharma.com","stockEarnings":[{"period":"1week","weight":0.0698},{"period":"1month","weight":0.411},{"period":"3month","weight":0.122},{"period":"6month","weight":0.1735},{"period":"1year","weight":1.5},{"period":"ytd","weight":-0.0171}],"compareEarnings":[{"period":"1week","weight":0.0062},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0259},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.005},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Clover Biopharmaceuticals Ltd is an investment holding company primarily engaged in the research and development, manufacture and commercialization of innovative vaccines. The Company’s products and candidates include Respiratory Syncytial Virus (RSV) Vaccine (SCB-1019), seasonal quadrivalent influenza vaccine AdimFlu-S, SCB-219M, COVID-19 Vaccine and others. The Company leverages the Trimer-Tag technology platform to conduct research and development (R&D) for innovative vaccines that can fulfill unmet need, with a focus on building a respiratory vaccine franchise and establishing a presence in the pediatric vaccine market. The Trimer-Tag is a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets. The Company conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.113925},{"month":2,"riseRate":0.4,"avgChangeRate":0.011169},{"month":3,"riseRate":0.2,"avgChangeRate":-0.104268},{"month":4,"riseRate":0.4,"avgChangeRate":-0.028136},{"month":5,"riseRate":0.4,"avgChangeRate":-0.154826},{"month":6,"riseRate":0.4,"avgChangeRate":-0.025093},{"month":7,"riseRate":0.6,"avgChangeRate":0.169081},{"month":8,"riseRate":0.6,"avgChangeRate":0.101417},{"month":9,"riseRate":0.5,"avgChangeRate":0.326004},{"month":10,"riseRate":0,"avgChangeRate":-0.070872},{"month":11,"riseRate":0.75,"avgChangeRate":0.569272},{"month":12,"riseRate":0.2,"avgChangeRate":-0.160916}],"exchange":"SEHK","name":"CLOVER BIO-B","nameEN":"CLOVER BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLOVER BIO-B(02197) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLOVER BIO-B,02197,CLOVER BIO-B股票,CLOVER BIO-B股票老虎,CLOVER BIO-B股票老虎国际,CLOVER BIO-B行情,CLOVER BIO-B股票行情,CLOVER BIO-B股价,CLOVER BIO-B股市,CLOVER BIO-B股票价格,CLOVER BIO-B股票交易,CLOVER BIO-B股票购买,CLOVER BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLOVER BIO-B(02197),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLOVER BIO-B(02197) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}